osteoporosis
Conditions
Brief summary
Change in total hip BMD at 24 months
Detailed description
Change in lumbar spine and femoral neck BMD at 24 months, Change in HRpQCT derived bone microarchitecture at 24 months, Changes in bone turnover markers during the course of the trial, Bone modelling and remodelling assessed by histomorphometry of bone biopsies, Increase in number and composition of osteoprogenitor cells in the bone marrow, Effect of romosozumab on glucose metabolism and interaction with changes in bone turnover markers and BMD
Interventions
Sponsors
Aarhus University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total hip BMD at 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in lumbar spine and femoral neck BMD at 24 months, Change in HRpQCT derived bone microarchitecture at 24 months, Changes in bone turnover markers during the course of the trial, Bone modelling and remodelling assessed by histomorphometry of bone biopsies, Increase in number and composition of osteoprogenitor cells in the bone marrow, Effect of romosozumab on glucose metabolism and interaction with changes in bone turnover markers and BMD | — |
Countries
Denmark
Outcome results
None listed